Moreover, the possible interaction between LAG-3 and other checkpoints, namely PD-1 and CTLA-4, holds significant promise in raising the bar and extending the landscape of melanoma immunotherapy.17,31,32. The gene discussed is PDCD1; the disease is melanoma.